Targovax strengthens management team with the appointment of Torbjørn Furuseth as CFO; Erik Digman Wiklund to become CBO
Oslo, 13 September 2018: Targovax ASA (“Targovax” or “the Company”; OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, announces the appointment of Dr. Torbjørn Furuseth as CFO, effective 24 September 2018. Dr. Erik Digman Wiklund, currently Targovax’s CFO, will become Chief Business Officer, replacing Michael Bogenstaetter.Torbjørn joins from the clinical stage pharmaceutical company Lytix Biopharma, where he has served as CFO since February 2017, developing an integrated financing strategy and raising NOK 150 million in